<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843579</url>
  </required_header>
  <id_info>
    <org_study_id>20-12023093</org_study_id>
    <nct_id>NCT04843579</nct_id>
  </id_info>
  <brief_title>Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients</brief_title>
  <acronym>ClaSPd</acronym>
  <official_title>A Phase 2, Open-Label, Single-Arm Study of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of investigational&#xD;
      combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for&#xD;
      patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of&#xD;
      Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall&#xD;
      response rate of patients with relapsed/refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Overall Response Rate of Partial Response or Better</measure>
    <time_frame>Approximately 40 months</time_frame>
    <description>Overall response rate will be defined as percentage of participants who achieve Partial Response or Better according to the International Myeloma Working Group response criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Adverse events will be determined by Events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The frequency of adverse events will be collected in tabular summary from when a participant consent to study until end of study or patient participant starts a new treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Myeloma Multiple</condition>
  <condition>Myeloma</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selinexor&#xD;
• Given orally at a dose of 60 mg on days 1, 8, and 15 of a 28-day cycle.&#xD;
Dexamethasone&#xD;
Given orally at a dose of 40 mg on days 1, 8, 15 and 22 of a 28-day cycle.&#xD;
Subjects will receive a prescription for dexamethasone 4 mg tablets (generic).&#xD;
Clarithromycin&#xD;
Given orally at a dose of 500 mg twice a day on days 1-28 of a 28-day cycle.&#xD;
Subjects will receive a prescription for clarithromycin 250 or 500 mg tablets (generic) for oral administration.&#xD;
Pomalidomide&#xD;
Given orally at a dose of 4 mg daily on days 1-21 of a 28-day cycle.&#xD;
Subjects will receive a 21-day supply of pomalidomide 1, 2, 3, or 4 mg capsules for oral administration for each treatment cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Given as 60 mg oral capsule</description>
    <arm_group_label>Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Given as 500 mg oral capsule</description>
    <arm_group_label>Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Given as 4 mg oral capsule</description>
    <arm_group_label>Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given as 40 mg oral capsule</description>
    <arm_group_label>Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent in accordance with federal, local, and institutional&#xD;
             guidelines.&#xD;
&#xD;
          -  Age ≥18 and &lt;75 years at the time of informed consent.&#xD;
&#xD;
          -  Confirmed diagnosis of multiple myeloma&#xD;
&#xD;
          -  Symptomatic multiple myeloma per IMWG guidelines.&#xD;
&#xD;
          -  Measurable disease as defined by at least one of the following: a. Serum M-protein ≥&#xD;
             0.5 g/dL by serum protein electrophoresis (SPEP) or, for IgA myeloma, by quantitative&#xD;
             IgA, and/or b. Urinary M-protein excretion at least 200 mg/24 hours, and/or c. Serum&#xD;
             FLC ≥ 100 mg/L, provided that FLC ratio is abnormal, and/or d. If serum protein&#xD;
             electrophoresis is felt to be unreliable for routine M-protein measurement (e.g., for&#xD;
             IgA MM), then quantitative Ig levels by nephelometry or turbidimetry are acceptable.&#xD;
&#xD;
          -  Relapsed and refractory multiple myeloma with documented evidence of PD after&#xD;
             achieving at least SD for ≥ 1 cycle during a previous MM regimen (i.e., relapsed MM),&#xD;
             and ≤ 25% response (i.e., patients never achieved ≥ MR) or PD during or within 60 days&#xD;
             from the end of the most recent MM regimen (i.e., refractory MM).&#xD;
&#xD;
          -  Previously received one to four prior lines of therapy and be pomalidomide-naïve.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented active systemic light chain amyloidosis.&#xD;
&#xD;
          -  Active plasma cell leukemia.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status greater than 2.&#xD;
&#xD;
          -  Persistent non-hematological toxicity (except for peripheral neuropathy) from a prior&#xD;
             treatment which has not resolved to at least Grade 2 or better by Cycle 1 Day 1&#xD;
             (C1D1).&#xD;
&#xD;
          -  Severe hepatic dysfunction with either: a. Total bilirubin &gt; 2x ULN (&gt; 3x ULN in&#xD;
             subjects with Gilbert's syndrome [hereditary indirect hyperbilirubinemia]), and/or b.&#xD;
             AST and/or ALT &gt; 2.5x ULN&#xD;
&#xD;
          -  Severe renal dysfunction with an estimated creatinine clearance of &lt; 15 mL/min&#xD;
             calculated using the Cockcroft and Gault formula.&#xD;
&#xD;
          -  Impaired hematopoietic function with either: a. White blood cell count &lt; 1,500/mm3,&#xD;
             and/or b. Absolute neutrophil count &lt; 1000/mm3, and/or c. Hemoglobin &lt; 8.0 g/dL,&#xD;
             and/or d. Platelet count &lt; 100,000/mm3 (for patients in whom ≥ 50% of bone marrow&#xD;
             nucleated cells are plasma cells, platelets ≥ 75,000/mm3 are acceptable).&#xD;
&#xD;
          -  Blood (or blood product) transfusions or blood growth factors within 7 days of C1D1.&#xD;
             Use of hematopoietic growth factor support is acceptable, including erythropoietin&#xD;
             (EPO), darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte&#xD;
             macrophage colony stimulating factor (GM-CSF), and platelet stimulators (e.g.,&#xD;
             eltrombopag or romiplostim). However, patients must be platelet transfusion&#xD;
             independent for &gt; 1 week in order to be enrolled in the study.&#xD;
&#xD;
          -  Radiation, chemotherapy or immunotherapy, or any other anticancer therapy within 2&#xD;
             weeks prior to C1D1, or radio-immunotherapy within 6 weeks prior to C1D1. Patients on&#xD;
             long-term glucocorticoids during Screening do not require a washout period. Prior&#xD;
             radiation is permitted for treatment of fractures or to prevent fractures, as well as&#xD;
             for pain management.&#xD;
&#xD;
          -  Patients with history of spinal cord compression with residual paraplegia.&#xD;
&#xD;
          -  Treatment with an investigational anti-cancer therapy within 3 weeks prior to C1D1.&#xD;
&#xD;
          -  Prior autologous stem cell transplantation &lt; 1 month, or allogeneic stem cell&#xD;
             transplantation &lt; 3 months prior to C1D1.&#xD;
&#xD;
          -  Active graft versus host disease after allogeneic stem cell transplantation.&#xD;
&#xD;
          -  Life expectancy &lt; 3 months.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to C1D1.&#xD;
&#xD;
          -  Active, unstable cardiovascular function with either: a. Symptomatic ischemia, b.&#xD;
             Uncontrolled clinically significant conduction abnormalities (e.g., patients with&#xD;
             ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree&#xD;
             atrioventricular (AV) block or asymptomatic left anterior fascicular block/right&#xD;
             bundle branch block (LAFB/RBBB) will not be excluded), c. Congestive heart failure&#xD;
             (CHF) of New York Heart Association (NYHA) Class ≥ 3, d. Myocardial infarction (MI)&#xD;
             within 6 months prior to C1D1, or e. Screening 12-lead ECG showing a baseline QT&#xD;
             interval as corrected by Bazett's formula (QTc) &gt; 470 msec&#xD;
&#xD;
          -  Uncontrolled active hypertension&#xD;
&#xD;
          -  Venous thromboembolism within 6 months prior to C1D1 or a known inherited&#xD;
             thrombophilia&#xD;
&#xD;
          -  Inability to receive either prophylactic or therapeutic anticoagulation as determined&#xD;
             appropriate by the Investigator&#xD;
&#xD;
          -  Uncontrolled active infection requiring parenteral antibiotics, antivirals, or&#xD;
             antifungals within one week prior to C1D1&#xD;
&#xD;
          -  Any active gastrointestinal dysfunction that prevents the patient from swallowing&#xD;
             tablets or interferes with absorption of study treatment&#xD;
&#xD;
          -  Currently pregnant or breastfeeding. Lactating females must agree not to breast feed&#xD;
             while receiving selinexor, pomalidomide and/or clarithromycin&#xD;
&#xD;
          -  A serious psychiatric or medical condition which, in the opinion of the Investigator,&#xD;
             could interfere with treatment&#xD;
&#xD;
          -  Hypersensitivity or contraindication to selinexor, pomalidomide, dexamethasone and/or&#xD;
             clarithromycin&#xD;
&#xD;
          -  Prior exposure to a SINE compound, including selinexor&#xD;
&#xD;
          -  Concomitant use of any strong CYP3A4 and/or CYP1A2 inhibitors (see Appendix 1)&#xD;
&#xD;
          -  Unable to obtain commercial clarithromycin, pomalidomide and dexamethasone through a&#xD;
             regular and/or specialty pharmacy.&#xD;
&#xD;
          -  Unable or unwilling to register into the mandatory POMALYST REMSTM program and comply&#xD;
             with its requirements.&#xD;
&#xD;
          -  Male and female patients unwilling or unable to use effective methods of contraception&#xD;
             throughout the study and for three months following the last dose. Acceptable methods&#xD;
             of contraception are condoms with contraceptive foam, oral, implantable or injectable&#xD;
             contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal&#xD;
             gel, or a sexual partner who is surgically sterilized or post-menopausal. Note that&#xD;
             female patients of childbearing potential must agree to use dual methods of&#xD;
             contraception and have a negative serum pregnancy test at Screening and male patients&#xD;
             must use an effective barrier method of contraception if sexually active with a female&#xD;
             of child-bearing potential.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Monge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen Research Nurse, RN</last_name>
    <phone>646-962-6500</phone>
    <email>kap9111@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado, Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Forsberg, MD</last_name>
      <email>peter.forsberg@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Forsberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian Brooklyn Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Eshan Patel, MD</last_name>
      <email>esp9014@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Eshan Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine - Multiple Myeloma Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kathleen Research Nurse, RN</last_name>
      <phone>646-962-6500</phone>
      <email>kap9111@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Research Nurse, RN</last_name>
      <phone>646-962-6500</phone>
      <email>naa9101@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jorge Monge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adriana Rossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 10, 2021</study_first_submitted>
  <study_first_submitted_qc>April 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

